Holen Sie sich die Stockscreener-App
3.70
3.64%
0.13
Handel nachbörslich:
3.80
0.10
+2.70%
Schlusskurs vom Vortag:
$3.57
Offen:
$3.6
24-Stunden-Volumen:
4.26M
Relative Volume:
1.08
Marktkapitalisierung:
$667.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-217.44M
KGV:
-1.7051
EPS:
-2.17
Netto-Cashflow:
$-205.20M
1W Leistung:
+7.56%
1M Leistung:
-1.07%
6M Leistung:
+18.97%
1J Leistung:
+13.15%
1-Tages-Spanne:
$3.56
$3.87
1-Wochen-Bereich:
$3.29
$3.87
52-Wochen-Spanne:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Vergleichen Sie PRME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.70 | 644.42M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
Prime Medicine, Inc. (PRME) announces NEJM publication of PM359 data - MSN
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
Prime: Maintaining "Buy" On Solidified Catalysts For Wilson's Disease And Beyond - Seeking Alpha
Prime Medicine (NYSE:PRME) Trading Down 3.3%Here's What Happened - MarketBeat
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases - Insider Monkey
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data - Insider Monkey
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Lifesci Capital Predicts Prime Medicine FY2025 Earnings - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 3.8%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 4.2%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded at Lifesci Capital - MarketBeat
LifeSci Capital Initiates Coverage of Prime Medicine (PRME) with Outperform Recommendation - Nasdaq
How Prime Medicine Inc. stock reacts to oil pricesEvening Star Patterns & Free Dynamic Investment Techniques - bollywoodhelpline.com
Lifesci Capital Begins Coverage on Prime Medicine (NYSE:PRME) - MarketBeat
LifeSci Capital Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $6 - 富途牛牛
Prime Medicine: Buy Rating on Prime Editing Platform Targeting High-Value Liver and Lung Genetic Diseases, Led by PM577 in Wilson’s Disease - TipRanks
Prime Medicine initiated with an Outperform at LifeSci Capital - TipRanks
LifeSci Initiates Prime Medicine at Outperform With $6 Price Target - marketscreener.com
Prime Medicine Earnings Notes - Trefis
Prime Medicine, Inc.(NasdaqGM: PRME) added to S&P Biotechnology Select Industry Index - marketscreener.com
Prime Medicine announces NEJM publication of PM359 data - MSN
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Recap: How Prime Medicine Inc. stock reacts to oil pricesWatch List & Safe Entry Trade Reports - Улправда
Risks Report: Why Prime Medicine Inc. stock remains resilient2025 Market Trends & Real-Time Buy Signal Notifications - Улправда
What technical charts say about Prime Medicine Inc. stockEarnings Overview Report & AI Powered Market Entry Strategies - Улправда
Why Prime Medicine Inc. stock remains resilientTrade Exit Summary & Weekly High Return Stock Forecasts - Улправда
Can Prime Medicine Inc. stock hit record highs againJuly 2025 News Drivers & Weekly High Conviction Ideas - Улправда
Can Prime Medicine Inc. stock withstand economic slowdownTrade Signal Summary & Weekly Top Gainers Alerts - Улправда
Is Prime Medicine Inc. stock in correction or buying zone2025 Stock Rankings & Consistent Growth Equity Picks - DonanımHaber
Profit Recap: How Prime Medicine Inc. stock reacts to oil pricesRate Hike & Accurate Intraday Trading Signals - Улправда
Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying - simplywall.st
Prime Medicine’s Stock Fluctuations: How Genomic Advances Steer Performance - StocksToTrade
Prime Medicine (NYSE:PRME) Shares Gap UpShould You Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Gap UpStill a Buy? - MarketBeat
Prime Medicine Announces The New England Journal of - GlobeNewswire
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease - Sahm
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Prime Medicine (NYSE:PRME) Stock Price Up 10.2%Still a Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Up 11.1%Here's What Happened - MarketBeat
Will Prime Medicine Inc. stock deliver better than expected guidance2025 Sector Review & Safe Capital Preservation Plans - Newser
Prime Medicine (PRME) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 7.2%Here's Why - MarketBeat
PRME: Prime editing advances with focused clinical programs and data expected in 2027 - TradingView — Track All Markets
Prime Medicine (PRME) Competitors and Alternatives 2025 - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference - The Manila Times
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):